Skip to main content

Table 3 The prevalence (p) of HIV treatment failure based on HAART failure, immunological, virological, and clinical definition when the study omitted in Ethiopia

From: HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis

Study omittedHAART failure P (95%CI)Immunological failure P (95%CI)Virological failure P (95%CIClinical failure P (95% CI)
Bokretsion BG et al./201715.3 (10.8–19.9)9.7 (6.3–13.2)4.5 (2.3–6.7)5.6 (4.2–7.1)
Yassin S /201715.5 (10.9–20.1)10.5 (6.9–14.1)__5.5 (4.1–7.1)
Zeleke A/201615.6 (11.0–20.2)10.6 (7.0–14.1)__6.7 (4.9–8.4)
Yimer YT/201515.4 (10.8–19.9)9.8 (6.4–13.3)6.5 (2.7–10.3)6.3 (4.4–8.2)
Bacha T et al./201216.1 (10.9–21.3)10.5 (6.6–14.4)__6.4 (4.3–8.4)
Ayalew MB et al./201617.3 (13.5–21.2)10.8 (7.1–14.4)6.0 (2.9–9.2)__
Sisay MM et al./201816.9 (12.6–21.2)10.9 (7.7–14.1)__6.4 (4.4–8.4)
Tsegaye AT et al./201615.5 (10.9–20.1)10.5 (6.9–14.1)__6.7 (5.0–8.4)
Teshome W/2015__9.8 (6.3–13.2)____
Hailu GG et al./2015__10.5 (6.9–14.1)4.4 (2.0–6.9)__
Yayehirad AM et al./2013__9.3 (6.3–12.4)____
Workneh N et al./2009__10.1 (6.6–13.6)___6.4 (4.6–8.2)
Sisay C et al./201715.2 (10.8–19.5)9.8 (6.4–13.2)6.4 (2.4–10.4)6.5 (4.7–8.4)
Abdissa A et al./2014____5.6 (2.7–8.6)__
Combined15.8 (11.6–20.1)10.2 (6.8–13.6)5.6 (2.9–8.3)6.3 (4.6–7.9)
  1. __ denotes no estimation due to lack of original studies
\